212 related articles for article (PubMed ID: 1965445)
1. [Usefulness of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), enolase (NSE) and thymidine-kinase (TK) in the monitoring and prognosis of primary carcinoma of the lung].
De Angelis G; De Marinis F; Bigioni D; Migliorino MR; Alma MG; Pigorini F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):135-40. PubMed ID: 1965445
[No Abstract] [Full Text] [Related]
2. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of neuron specific enolase and tissue polipeptidic antigen for the management of patients with lung cancer.
Spinazzi A; Soresi E; Borghini U; Boffi R; Vigorelli R; Scoccia S
J Nucl Med Allied Sci; 1990; 34(4 Suppl):141-5. PubMed ID: 1965446
[No Abstract] [Full Text] [Related]
4. Biomarkers and IL-2R in lung cancer.
Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
[TBL] [Abstract][Full Text] [Related]
5. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
[TBL] [Abstract][Full Text] [Related]
6. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
8. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
9. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
[TBL] [Abstract][Full Text] [Related]
10. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis.
Gronowitz JS; Bergström R; Nôu E; Påhlman S; Brodin O; Nilsson S; Källander CF
Cancer; 1990 Aug; 66(4):722-32. PubMed ID: 2167141
[TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer.
Nieder C; Andratschke N; Jeremic B; Molls M
Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976
[TBL] [Abstract][Full Text] [Related]
13. [Role of biological tumor markers CEA, Cyfra-21, NSE, TU M2-PK in diagnosis and treatment of lung cancer].
Lazarev SM; Massard Zh; Reshetov AV; Nikolaev GV; Volgin GN; Osipov EV; Lomteva EIu; Nokhrin AV; Kakysheva OE
Vestn Khir Im I I Grek; 2010; 169(1):39-43. PubMed ID: 20387605
[TBL] [Abstract][Full Text] [Related]
14. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
15. Multiple tumour markers for diagnosis, management and follow-up of potentially resectable lung cancer.
Ratto GB; Mereu C; Rovida S
Panminerva Med; 1993 Dec; 35(4):186-92. PubMed ID: 8202329
[TBL] [Abstract][Full Text] [Related]
16. [Biological markers in lung cancer].
Nikliński J; Furman M
Pneumonol Alergol Pol; 1991; 59(5-6):253-9. PubMed ID: 1668877
[No Abstract] [Full Text] [Related]
17. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
Jin B; Huang AM; Zhong RB; Han BH
Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
[TBL] [Abstract][Full Text] [Related]
18. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
19. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of carcinoembryonic antigen (CEA) and brain-type creatine kinase (CK-BB) in serum from patients with carcinoma of the lung.
Nikliński J; Furman M; Laudański J; Pałynyczko Z; Welk M
Neoplasma; 1991; 38(2):129-35. PubMed ID: 1645850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
